We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

32 hedge funds and large institutions have $51M invested in Xilio Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

19% more capital invested

Capital invested by funds: $42.8M → $51M (+$8.14M)

14% more funds holding

Funds holding: 28 → 32 (+4)

0.04% more ownership

Funds ownership: 4.14% → 4.18% (+0.04%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
32
Holders Change
+4
Holders Change %
+14.29%
% of All Funds
0.51%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
5
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RSCM
Rock Springs Capital Management
Maryland
+$244K
2
Citadel Advisors
Citadel Advisors
Florida
+$225K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$56.1K
4
Morgan Stanley
Morgan Stanley
New York
+$15.5K
5
Northern Trust
Northern Trust
Illinois
+$12.6K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$57.4K
2
Millennium Management
Millennium Management
New York
-$31.8K
3
Bank of America
Bank of America
North Carolina
-$18.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$8.89M – – –
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$8.75M – – –
OCA
3
Octagon Capital Advisors
New York
$7.69M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$6.07M – – –
RVM
5
RiverVest Venture Management
Missouri
$4.57M – – –
RSCM
6
Rock Springs Capital Management
Maryland
$4.57M +$244K +5,563 +6%
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.82M – – –
AG
8
Artal Group
Luxembourg
$1.43M – – –
HMC
9
Harvard Management Company
Massachusetts
$1.32M – – –
TOCUITCONY
10
Trustees of Columbia University in the City of New York
New York
$791K – – –
Bank of America
11
Bank of America
North Carolina
$720K -$18.2K -414 -2%
SCM
12
Soleus Capital Management
Connecticut
$719K – – –
Fidelity International
13
Fidelity International
Bermuda
$695K – – –
LCM
14
Laurion Capital Management
New York
$454K – – –
BCM
15
Bridgeway Capital Management
Texas
$351K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$269K – – –
Citadel Advisors
17
Citadel Advisors
Florida
$228K +$225K +5,117 New
BlackRock
18
BlackRock
New York
$162K +$4.92K +112 +3%
Morgan Stanley
19
Morgan Stanley
New York
$96.8K +$15.5K +352 +19%
Renaissance Technologies
20
Renaissance Technologies
New York
$60K -$57.4K -1,307 -49%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$56.9K +$56.1K +1,277 New
CC
22
Cannell Capital
Wyoming
$54K – – –
Northern Trust
23
Northern Trust
Illinois
$53.6K +$12.6K +286 +31%
Millennium Management
24
Millennium Management
New York
$53K -$31.8K -725 -38%
State Street
25
State Street
Massachusetts
$49.9K – – –
1
2

XLO Hedge Fund Activity: Q1 2023 in Review

32 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2023, worth a combined $51M — up 19% from $42.8M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new XLO positions and 0 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Rock Springs Capital Management, adding an estimated $244K. The largest seller was Renaissance Technologies, cutting an estimated $57.4K.

  • 32 institutional investors held Xilio Therapeutics (XLO) as of Q1 2023, up from 28 in Q4 2022.
  • Funds reported $51M of Xilio Therapeutics stock for Q1 2023, up 19% quarter-over-quarter.
  • 4 funds opened new Xilio Therapeutics positions in Q1 2023 and 0 closed out, a net change of +4 holders.
  • The largest Xilio Therapeutics buyer in Q1 2023 was Rock Springs Capital Management, an estimated $244K added.
  • The largest Xilio Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $57.4K sold.

Based on aggregated 13F filings for Q1 2023.